Literature DB >> 21063024

Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.

Yi Lin1, Michael P Gustafson, Peggy A Bulur, Dennis A Gastineau, Thomas E Witzig, Allan B Dietz.   

Abstract

Immunosuppression is a known risk factor for B-cell non-Hodgkin lymphoma (NHL), yet mechanisms of tumor-associated immunosuppression remain to be fully characterized. We examined the immunophenotype of 40 NHL patients and 27 age-matched healthy volunteers to better understand systemic immune suppression. NHL peripheral blood mononuclear cells had significantly decreased interferon-γ production and proliferation. This suppression was not the result of regulatory T cells, interleukin-6 or interleukin-10, as these factors were not different between NHL and healthy volunteers (controls). We were able to restore T-cell proliferation by removing NHL monocytes, suggesting that these monocytes are suppressive. This suppression was mediated in part through arginine metabolism as exogenous arginine supplementation partially overcame monocytes' suppression of T-cell proliferation in vitro and NHL patients had elevated arginase I in their plasma. NHL monocytes had impaired STAT1 phosphorylation and interferon-α production to CpG stimulation and a dendritic cell differentiation deficiency. Further studies demonstrated that monocytes from NHL patients had decreased HLA-DR and Tumor necrosis factor-α receptor II (CD120b) expression compared with controls (CD14(+)HLA-DR(low/-)CD120b(low)). Patients with increased ratios of CD14(+)HLA-DR(low/-) monocytes had more aggressive disease and suppressed immune functions. In summary, we report that CD14(+)HLA-DR(low/-) monocytes are a major and multifactorial contributor to systemic immunosuppression in NHL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21063024      PMCID: PMC3035079          DOI: 10.1182/blood-2010-05-283820

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas.

Authors:  L F Porrata; K Ristow; T E Witzig; N Tuinistra; T M Habermann; D J Inwards; S M Ansell; I N Micallef; P B Johnston; S N Markovic
Journal:  Leukemia       Date:  2007-06-21       Impact factor: 11.528

2.  Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.

Authors:  Yasuhiro Oki; Kazuhito Yamamoto; Harumi Kato; Yachiyo Kuwatsuka; Hirofumi Taji; Yoshitoyo Kagami; Yasuo Morishima
Journal:  Eur J Haematol       Date:  2008-08-06       Impact factor: 2.997

3.  Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

Authors:  S M Ansell; M Stenson; T M Habermann; D F Jelinek; T E Witzig
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

4.  Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma.

Authors:  Nozomi Niitsu; Masataka Okamato; Hirokazu Nakamine; Tadashi Yoshino; Jun-ichi Tamaru; Shigeo Nakamura; Masaki Higashihara; Masami Hirano
Journal:  Eur J Haematol       Date:  2002-02       Impact factor: 2.997

5.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

Authors:  Pedro Farinha; Hamid Masoudi; Brian F Skinnider; Karey Shumansky; John J Spinelli; Karamjit Gill; Richard Klasa; Nicolas Voss; Joseph M Connors; Randy D Gascoyne
Journal:  Blood       Date:  2005-06-02       Impact factor: 22.113

6.  Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma.

Authors:  Ewa Lech-Maranda; Jacques Bienvenu; Anne-Sophie Michallet; Roch Houot; Tadeusz Robak; Bertrand Coiffier; Gilles Salles
Journal:  Eur Cytokine Netw       Date:  2006-03       Impact factor: 2.737

7.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

8.  Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.

Authors:  Jeffrey S Weber; Hassan Zarour; Bruce Redman; Uwe Trefzer; Steven O'Day; Alfons J M van den Eertwegh; Ernest Marshall; Stefan Wagner
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

9.  Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas.

Authors:  Dipti Talaulikar; Ayesha Choudhury; Bruce Shadbolt; Michael Brown
Journal:  Leuk Lymphoma       Date:  2008-05

10.  CpG oligodeoxynucleotides as immunotherapy in cancer.

Authors:  Bernd Jahrsdörfer; George J Weiner
Journal:  Update Cancer Ther       Date:  2008-03
View more
  89 in total

1.  Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma.

Authors:  Chongyang Wu; Xiangyang Wu; Xiaoni Zhang; Ye Chai; Qi Guo; Lijuan Li; Lingling Yue; Jun Bai; Zhiping Wang; Liansheng Zhang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Expansion of a subset of CD14highCD16negCCR2low/neg monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infection.

Authors:  Lucio Gama; Erin N Shirk; Julia N Russell; Karina I Carvalho; Ming Li; Suzanne E Queen; Jorge Kalil; M Christine Zink; Janice E Clements; Esper G Kallas
Journal:  J Leukoc Biol       Date:  2012-02-24       Impact factor: 4.962

3.  Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma.

Authors:  Hideaki Nitta; Yasuhito Terui; Masahiro Yokoyama; Yuko Mishima; Noriko Nishimura; Kyoko Ueda; Yoshiharu Kusano; Naoko Tsuyama; Kengo Takeuchi; Yoshinobu Kanda; Kiyohiko Hatake
Journal:  Haematologica       Date:  2014-09-26       Impact factor: 9.941

4.  Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma.

Authors:  Shogo Kumagai; Masaharu Tashima; Jun Fujikawa; Makoto Iwasaki; Yoshihiro Iwamoto; Yuki Sueki; Akiko Fukunaga; Soshi Yanagita; Momoko Nishikori; Akifumi Takaori-Kondo; Nobuyoshi Arima
Journal:  Int J Hematol       Date:  2014-04-23       Impact factor: 2.490

5.  Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL).

Authors:  Michael P Gustafson; Roshini S Abraham; Yi Lin; Wenting Wu; Dennis A Gastineau; Clive S Zent; Allan B Dietz
Journal:  Br J Haematol       Date:  2011-11-03       Impact factor: 6.998

6.  Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation.

Authors:  A Kansagra; D J Inwards; S M Ansell; I N Micallef; P B Johnston; W J Hogan; S N Markovic; L F Porrata
Journal:  Bone Marrow Transplant       Date:  2017-10-16       Impact factor: 5.483

7.  Immunosuppressive monocytes (CD14+/HLA-DRlow/-) increase in childhood precursor B-cell acute lymphoblastic leukemia after induction chemotherapy.

Authors:  D S Lima; R P G Lemes; D M Matos
Journal:  Med Oncol       Date:  2018-02-10       Impact factor: 3.064

Review 8.  Consensus reference gene(s) for gene expression studies in human cancers: end of the tunnel visible?

Authors:  R N Sharan; S Thangminlal Vaiphei; Saibadaiahun Nongrum; Joshua Keppen; Mandahakani Ksoo
Journal:  Cell Oncol (Dordr)       Date:  2015-09-18       Impact factor: 6.730

9.  Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity.

Authors:  Rahul Chavan; Daniela Salvador; Michael P Gustafson; Allan B Dietz; Wendy Nevala; Svetomir N Markovic
Journal:  Cancer Immunol Res       Date:  2013-11-18       Impact factor: 11.151

Review 10.  Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.

Authors:  Stefano Ugel; Francesco De Sanctis; Susanna Mandruzzato; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.